SES* was the FDA NMIBC darling but they fell from grace.  .37 to OVER SIX BUCKS A SHARE. 

But then is was clear SES* treatments are not good enough. They fell fast and hard. 

The market pivot is in progress. 

LOOK TO THERALASE UPDATES SOON!!